Kornimate/medical-research-clean huggingface dataset:
a trial for patients with advanced/recurrent endometrial cancer

Conditions: Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial

Summary: the intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. this phase ii trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.


Eligibility criteria:
inclusion criteria: * patients must have recurrent or persistent endometrial adenocarcinoma, which is refractory to curative therapy or established treatments. * patients must have measurable disease. * patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma. * patients must have signed an approved informed consent. * patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception during the study and for at least 3 months following the last dose of pemetrexed. * patients must discontinue nonsteroidal anti-inflammatory (nsaids) medications 2-5 days prior to and for 1-2 days after receiving pemetrexed, depending on the half-life of the nsaids treatment. * patients must agree to this schedule in conjunction with every dose of pemetrexed. * patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting 7 days prior to the first treatment with pemetrexed. * patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after the last dose of pemetrexed. * patients must receive 4 mg dexamethasone by mouth twice daily, 1 day prior to the dose, the day of and the day after every dose of pemetrexed. * patients must receive a 1000 mcg vitamin b12 injection 7 days prior to receiving the first treatment with pemetrexed. * patients must agree to receive 1000 mcg vitamin b12 injection every 9 weeks until 3 weeks after the last dose of pemetrexed. exclusion criteria: * patients who have had prior therapy with pemetrexed * patients who have received radiation to more than 25% of marrow bearing areas
comparison of oral ivermectin and permethrin 5% lotion in treatment of pediculosis capitis

Conditions: Pediculosis

Summary: in children, pediculosis is a common ectoparasitic infestation. infestation of head lice (pediculus humanus capitis) causes a variety of physical symptoms, including pruritus, excoriation, cervical lymphadenopathy, and conjunctivitis1. it also has a number of negative social consequences, including parental anxiety and stigmatization of infested children2. it is a significant public health issue that primarily affects school-aged children aged 8 to 113. in developing nations, prevalence rates of up to 40% have been reported4. the four urban areas of kpk (nwfp) reported prevalence of 36.7%5. people with a low socioeconomic background and poor hygiene are more likely to be affected6. pediculosis capitis has been treated using a variety of treatment modalities. they include both physician prescription and over-the-counter medications. permethrin or ivermectin had been used topically or orally. permethrin is a neurotoxin that is synthesized. it is a pyrethroid neurotoxic that targets voltage-sensitive sodium ion receptors in the neurological system of the insect, triggering nerve depolarization, hyperexcitation, muscular paralysis, and, eventually, parasite death7. ivermectin is antiparasitic medication, it is possible to treat diseases like lymphatic filariasis, and ectoparasite infestations, primarily scabies, with ivermectin because it binds to glutamate gated chloride ion receptors of invertebrates and disrupts neurotransmission8. the rationale of this study is to study while comparing effectiveness of oral ivermectin and topical permethrin in management of pediculosis. the topical medication usage is problematic and had reported drug resistance9. there has been less regional or national research on the effectiveness of oral ivermectin, so doctors less frequently use it in our department. instead, the patients are treated for pediculosis capitis with topical permethrin.


Eligibility criteria:
inclusion criteria: both genders with live detected on clinical examination and by combing wet hair with a fine toothed lice detection comb ages 8-36 years weight \>15 kgs exclusion criteria: pregnancy breast feeding using any pediculicidal medication within the preceding two weeks of treatment hairstyle that may be difficult to comb

Keywords: ivermectin permethrin 5% lotion
effects of a ketogenic diet on pcos outcomes

Conditions: Polycystic Ovary Syndrome

Summary: the aim of the study is to investigate the effects of a low calorie mediterranean ketogenic diet on polycystic ovary syndrome (pcos) related outcomes.

fourteen overweight women with diagnosis of polycystic ovary syndrome (pcos) will undergo to a low calorie ketogenic mediterranean diet with phyoextracts (kemephy) for 12 week. changes in body weight, body mass index (bmi), fat body mass (fbm), lean body mass (lbm), visceral adipose tissue (vat), insulin, glucose, homa-ir, total cholesterol, low density lipoprotein (ldl), high density lipoprotein (hdl(, triglycerides (tgs), total and free testosterone, luteinizing hormone (lh), follicle stimulating hormone (fsh); dehydroepiandrosterone sulfate (dheas), estradiol, progesterone, sex hormone binding globulin (shbg) and ferriman gallwey score will be evaluated.

Eligibility criteria:
inclusion criteria: diagnosis of pcos according rotterdam criteria (at least 2 of 3 between * oligo/anovulation * hyperandrogenism * clinical (hirsutism or less commonly male pattern alopecia) or biochemical (raised fai or free testosterone) polycystic ovaries on ultrasound other inclusion criteria * fertile age (18-45 years); * bmi\> 25 kg/m2, * desire to lose weight; * acceptance not to use contraceptives during the experimental period exclusion criteria: * pregnancy and lactation, * hormonal therapy and/or insulin-sensitizers in the last 2 months, * hepatic, renal and heart diseases
covid19-or (sars-cov-2): observation,risk & recovery

Conditions: Exploring Risk Assessment and Recovery From COVID-19 Infection in Hospitalised Patients

Summary: a novel coronavirus, designated corona virus disease 2019 (covid-19) has resulted in a pandemic at the time of writing (27th april) the reported number of confirmed cases exceeding 3 million and over 200000 associated deaths. the burden on global critical care has been considerable. as of 24th april there have been 8752 uk critical care admissions with services under considerable strain, and a mortality rate over 50%. survivors of critical illness will require significant input. this study will perform mixed methods to provide rich data on risk stratification and recovery from critical illness. recovery from a novel disease requires documenting and the study reports physical and psychological changes following hospital discharge in survivors. in addition qualitative interviews are being conducted with patients who have survived and been discharged from critical care along with their relatives and treating professionals, to better understand their needs during recovery.


Eligibility criteria:
inclusion criteria: 1. adults ≥18 years admitted to icu with sars-cov-2 and survived 2. relatives or friends and professionals involved in the care of these patients. exclusion criteria: 1. patients \<18 years; 2. patients with a negative test for sars-cov-2 or patients not tested due to absence of symptoms;
open-label study of the effects of montelukast in patients with chronic cough

Conditions: Coughing

Summary: montelukast, a leukotriene receptor antagonist, is likely to be effective in the treatment of chronic cough and this could be made objective by measuring cough threshold before and after two weeks of treatment.

chronic cough is typically defined as cough that persists for longer than 8 weeks and is the most common presenting symptom in adults who seek medical treatment in an ambulatory setting. prospective studies have shown that three conditions account for the etiologic cause of chronic cough in the largest part of immunocompetent, nonsmoking patients with normal chest radiograph findings. in order of frequency, they are upper airway cough syndrome (uacs), previously referred to as postnasal drip syndrome (pnds), asthma and gastroesophageal reflux disease (gerd). uacs comprises many different conditions including pnds, acute sinusitis, allergic rhinitis, non-allergic rhinitis (postinfectious rhinitis, rhinitis medicamentosa, vasomotor rhinitis, rhinitis due to physical or chemical irritants). cough occurs in all asthmatics, and in a subset of patients with cough-variant asthma (cva), it is the only presenting symptom. in these cases it is well controlled with inhaled corticosteroids and beta-2 agonists. gerd is another cause that should be contemplated when anti-tussive or anti-inflammatory/anti-allergic treatment do not render results and when there are presenting symptoms suggestive of it. moreover, factors like smoking and use of ace-inhibitors should also be taken into account. leukotrienes are very important agents in the inflammatory response. it is known that they are contributing significantly to the pathological processes in asthma. montelukast is a leukotriene receptor antagonist which blocks the bonding of leukotrienes to their receptors thus inhibiting their inflammatory, bronchoconstrictive and mucosecretory effects. multiple clinical trials have demonstrated the ability of the leukotriene antagonists to improve symptoms, pulmonary function and bronchial hyperresponsiveness in patients with asthma. however, not much is known about their effects in people with chronic cough. studies have been carried out in an attempt to find out the effects of montelukast in some forms of chronic cough. nevertheless, the impact of montelukast on objective parameters such as cough reflex threshold, has not been explored. the investigators also reckon that montelukast will affect exhaled breath temperature - a novel surrogate marker of airway inflammation recognized lately

Eligibility criteria:
inclusion criteria: * patients with chronic cough: cough persisting for more than 8 consecutive weeks exclusion criteria: * current use of ace-inhibitors * use of systemic steroids in the last 4 weeks * copd * pregnancy * concomitant severe disease * smoking
pneumatic retinopexy for primary rhegmatogenous retinal detachment: to steamroll or not

Conditions: Rhegmatogenous Retinal Detachment

Summary: this is a randomized controlled trial comparing displacement of macula and the rapidity of reattachment of macula between two different positioning techniques after pneumatic retinopexy : direct technique (patient is positioned so that the bubble is immediately placed directly over the retina break) and steamroller technique (patient is initially positioned face down for 4-6 hours and subsequently changes their head position so that the bubble is then placed directly over the retina break).

pneumatic retinopexy (pr) is an established treatment for rhegmatogenous retinal detachment (rrd). in our centre, pr is the most commonly performed procedure for primary rrd repair with a high retinal reattachment success rate. in this procedure, patients are required to position according to the site of pathology following injection of an intravitreal gas bubble. some practitioners position the patient so that the gas bubble is immediately apposed directly against the retinal break (direct technique). others favour the steamroller technique whereby the patient is initially positioned face down, then after 4-6 hours, the position is changed sequentially so that the bubble is rolled over the retina towards the break responsible for the detachment (steamroller technique). variable visual acuity (va) outcomes and metamorphopsia are common post-procedure complaints despite successful rrd repair with pr. it has been suggested that variability in functional outcomes may be associated with the timing and ease of reattachment of macula. the purpose of this prospective study is to evaluate whether the steamroller technique is superior to the direct technique in faster reattachment of macula with less macula displacement.

Eligibility criteria:
inclusion criteria: * primary rrd * causative breaks over superior 8 clock hours * single break or group of breaks * no or min proliferative vitreoretinopathy (pvr) (grade a or b) * other breaks or lattice in attached retina are allowed exclusion criteria: * retinal break in the inferior 4 clock hours in detached retina * pvr grade c or worse * significant media opacity (vitreous hemorrhage, dense cataract, cornea scar, etc) * pre-existing ocular pathology \[macula hole (mh), epiretinal membrane (erm), cystoid macula edema (cme), age-related macula degeneration, myopic degeneration, advanced glaucoma, uveitis, amblyopia etc\] or previous eye trauma with poor baseline vision * previous pars plana vitrectomy * age ≤18years old * inadequate physical or mental competence to maintain the required postoperative head position

Keywords: pneumatic retinopexy steamroll direct to break
feasibility of endoscopic pylorotomy in the treatment of refractory gastroparesis, pilot study.

Conditions: Gastroparesis

Summary: gastroparesis is a common chronic condition, disabling the limited therapeutic resources justifying the exploration of new therapeutic possibilities. by analogy to the technique of per oral endoscopic myotomy (poem), we believe that myotomy pyloric muscle (pop = per oral pyloromyotomy) endoscopically could become a treatment of choice in the refractory gastroparesis with drug treatments by attacking the pyloric obstacle often spastic that counteracts an effective gastric emptying.

experimental study, prospective, single-center, pop feasibility pilot in the treatment of refractory gastroparesis. patients with gastroparesis (significant prolongation of gastric emptying) unimproved by prokinetic treatment and meet all the eligibility criteria will be included after a period of reflection of two weeks minimum. 20 patients will be prospectively included 10 patients with diabetic gastroparesis, 10 patients with non-diabetic gastroparesis (post-surgical, post-sjogren, idiopathic). pop will be performed under general anesthesia in intubated-ventilated patients using a carbon dioxide (co2) inflator. the published standard technique and learned by our team on the pig model will be conducted: submucosal tunnel at the anterior surface of the gastric antrum starting 3-5 cm proximal to the pylorus front section to the fiber by fiber to the muscular pyloric, then closing the inlet tunnel by hemostatic clips. an evaluation of symptoms by the gastroparesis cardinal symptom index (iscc) of the quality of life of the patient assessment of upper gastrointestinal disorders-quality of life (pagi-qol), sf-36 and gastrointestinal quality of life index (giqli ) and gastric emptying by a scintigraphic gastric emptying will be carried out at 3 months.

Eligibility criteria:
inclusion criteria: * patient with refractory gastroparesis to drug treatment (post-diabetic, post-sjogren, postsurgical or idiopathic) * signed consent * affiliate or beneficiary of a french social security scheme exclusion criteria: * contraindications to gastroesophageal gastroduodenal endoscopy, * early unable to follow protocol, * contraindications to general anesthesia, * can not stop anticoagulants for the gesture, * can not stop antiplatelet agents for the gesture, * pregnant or lactating women, * gastric resection surgery history of pyloric * patients under guardianship, curatorship or safeguard justice, * disorders of hemostasis against-indicating the endoscopic procedure.

Keywords: refractory gastroparesis per oral pyloromyotomy
anti-thrombotic monotherapy with the heartmate 3 lvas

Conditions: Heart Failure; Cardiovascular Diseases

Summary: the purpose of this study is to obtain a single-center safety and feasibility data on patients managed with a single anti-thrombotic therapy and the incidence of thrombotic adverse events associated with heartmate 3 lvas therapy.

patients implanted with the heartmate 3 lvas in whom at least 6 months reduced anticoagulation therapy (inr range 1.5-1.9 along with antiplatelet therapy) has been accomplished safely will be screened for participation in the study. if inclusion criteria are met, patients will be transitioned to a single anti-thrombotic therapy with acetylsalicylic acid (asa) and anticoagulation with warfarin will be removed. asa will be administered in a minimum dose of 100 mg per day with dosage adjustments based on verifynow testing up to a maximum of 200 mg daily. the primary endpoint will be analyzed at 90 days after initiation of the single antiplatelet therapy.

Eligibility criteria:
inclusion criteria: * patients implanted with heartmate 3 lvas irrespective of intended goal of treatment of bridge to transplant or destination therapy * 6 months or more on reduced anti-coagulation regimen (target inr 1.5-1.9) free of thromboembolic and thrombotic complications * evidence of forward flow across the aortic valve (with aortic valve opening of at least 1:2 per cardiac cycle) at baseline echocardiography (echo) or after the speed optimization without a significant progression of heart failure based on a biomarker and complex clinical assessment follow-up exclusion criteria: * absence of an informed consent * presence of any prosthetic valve * known history of major thrombotic event e.g. dvt * known history of stroke * left atrial appendage in patients with atrial fibrillation or flutter not addressed by resection or exclusion at a time of the implant * evidence of any intracardiac thrombus * any clinical indication for use of long-term warfarin anticoagulation (e.g. known genetic thrombotic mutation, malignancy)

Keywords: single anti-thrombotic therapy mechanical circulatory support
evaluation of the quality of the transfusion practice at rigshospitalet, copenhagen university hospital

Conditions: Hemorrhage; Blood Transfusions

Summary: the purpose is to evaluate and improve transfusion practice


Eligibility criteria:
inclusion criteria: * hospitalized at rigshospitalet, copenhagen university hospital exclusion criteria: -
bowel preparation for inpatient colonoscopy

Conditions: Gastrointestinal Hemorrhage; Colon Cancer; Diverticulosis

Summary: this study will compare two strategies for bowel cleansing prior to inpatient colonoscopy: the entire preparation taken the night before the procedure versus half the preparation taken the night before the procedure, and the other half taken the morning of the procedure.


Eligibility criteria:
inclusion criteria: * any diagnosis for which colonoscopy is indicated exclusion criteria: * ileus * severe colitis/toxic megacolon * gastric retention * bowel perforation * gastrointestinal obstruction * gastroparesis that precludes oral bowel preparation * pregnant or lactating women * allergy to polyethylene glycol. * unable to give consent

Keywords: colonoscopy bowel preparation
resistive exercise and stretching in women with dysmenorrhea

Conditions: Dysmenorrhea Primary

Summary: this study highlights the importance of exercise for young women with primary dysmenorrhea. exercise can help relieve the symptoms of dysmenorrhea by increasing blood flow and promoting the release of endorphins. additionally, exercise can improve the overall quality of life by reducing stress and anxiety. a comprehensive comparison of the effects of especially resistant exercises and stretching exercises on menstrual pain is based on limited findings in the literature. therefore, this study aims to make a significant contribution to clinical practice by evaluating the effectiveness and feasibility of these exercise types.

primary dysmenorrhea is a common condition that seriously affects women's quality of life, and alternative methods other than pharmacotherapy are often investigated. exercise may play a potential role in reducing the symptoms of dysmenorrhea by increasing blood flow and promoting the release of endorphins. additionally, exercise can improve the overall quality of life by reducing stress and anxiety. however, studies comparing the specific effects of resistance exercises and stretching exercises on dysmenorrhea are limited and do not provide clear guidance on this subject. the aim of this study is to evaluate the effectiveness and feasibility of these two types of exercise in young women with primary dysmenorrhea. the results of the research can guide healthcare professionals by providing information on which type of exercise may be more effective in clinical practice. the importance of exercise as a non-pharmacological treatment option is emphasized, and it is aimed at making a significant contribution to the wide acceptance and application of such treatments.

Eligibility criteria:
inclusion criteria: * having a score of 60 points or above on the menstrual symptoms scale * having a regular menstrual cycle (24-35 days) * not doing any exercise regularly * being between the ages of 18 and 25 * nulliparity * being cooperative and oriented * volunteering to participate in the study exclusion criteria: * having a medical history of chronic disease (cardiopulmonary, neurological, thyroid gland diseases) * having a history of regular exercise * engaging in regular sexual activity * having undergone gynecological surgical procedures * using hormonal contraceptive drugs or intrauterine devices * using a drug that causes dysmenorrhea * pelvic pathology, pelvic inflammatory diseases, endometriosis, etc. having a disease that causes secondary dysmenorrhea * using antidepressant medication * having acute musculoskeletal system problems